|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 绿茶和红茶多酚类化合物的抗病毒活性在新型冠状病毒肺炎预防和治疗中的应用显示文摘新型冠状病毒SARS-CoV-2或nCoV的迅速传播,已引起世界各国的高度重视并采取严格的预防和隔离措施。这个新的单链RNA冠状病毒通过唾液和鼻腔分泌物传播。鉴于新型冠状病毒感染病例数日益增多,美国食品药品监督管理局(FDA)已授权紧急使用瑞德西韦(Remdesivir)治疗,但至今仍然没有任何一种药物获批准用于治疗COVID-19。另一种替代的方法是用一些已知具有抗病毒特性的天然物质分子进行治疗。有报道证实,绿茶中的表没食子儿茶素没食子酸酯(EGCG)和红茶中的茶黄素对各种病毒,特别是对单链RNA病毒具有抗病毒活性。最近的研究揭示了在SARS-CoV-2病毒上存在可能的结合位点,并研究了它们与茶叶多酚类化合物之间的相互作用。这篇综述中也关注到EGCG和茶黄素,特别是茶黄素-3,3'-双没食子酸酯(TF3)和病毒上的受体有非常明显的相互作用。有些对接实验研究重点关注了这些多酚类化合物在抗COVID-19病毒方面的活性。文章对现有报道和支持使用茶多酚化合物作为预防和治疗COVID-19可能的候选药物的证据进行了综述。 | SUSMIT Mhatre TISHYA Srivastava SHIVRAJ Naik VANDANA Patravale 陈宗懋(译) | 2021 | 中国茶叶2021，43，1： | 9 |
| 2 | Therapeutic targets and delivery challenges for Alzheimer's disease显示文摘Dementia,including Alzheimer’s disease,the 21st Centuryepidemic,is one of the most significant social and health crises which has currently afflicted nearly 44 million patients worldwide and about new 7.7 million cases are reported every year.This portrays the unmet need towards better understanding of Alzheimer’s disease pathomechanisms and related research towards more effective treatment strategies.The review thus comprehensively addresses Alzheimer’s disease pathophysiology with an insight of underlying multicascade pathway and elaborates possible therapeutic targets-particularly anti-amyloid approaches,anti-tau approaches,acetylcholinesterase inhibitors,glutamatergic system modifiers,immunotherapy,antiinflammatory targets,antioxidants,3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and insulin.In spite of extensive research leading to identification of newer targets and potent drugs,complete cure of Alzheimer’s disease appears to be an unreached holy grail.This can be attributed to their ineffective delivery across blood brain barrier and ultimately to the brain.With this understanding,researchers are now focusing on development of drug delivery systems to be delivered via suitable route that can circumvent blood brain barrier effectively with enhanced patient compliance.In this context,we have summarized current drug delivery strategies by oral,transdermal,intravenous,intranasal and other miscellaneous routes and have accentuated the future standpoint towards promising therapy ultimately leading to Alzheimer’s disease cure. | Preshita Desai Harshad Shete Rahul Adnaik John Disouza Vandana Patravale | 2015 | World Journal of Pharmacology2015，4，3： | 4 |
| 3 | Formulation and evaluation of Nanostructured Lipid Carrier( NLC ) -based gel of Valdecoxib 显示文摘 | JOSHI M PATRAVALE V | 2006 | Drug Dev Ind Pharm2006，32，8： | 1 |
| 4 | Nanostructured lipid cartier (NLC) based gel of celecoxib显示文摘 | Jashi M Patravale V | 2008 | lnt J Pharm2008，346，12： | 1 |
| 5 | Nanosuspensions:apromising drug delivery strategy显示文摘 | Patravale VB Date AA Kulkarni RM | 2004 | J Pharm Pharmacol2004，，： | 1 |
| 6 | Evaluation of novel lipid based formulation of β-Artemether and Lumefantrine in murine malaria model显示文摘 | Sushant Patil Shital Suryavanshi Sulabha Pathak Shobhona Sharma Vandana Patravale | 2013 | International Journal of Pharmaceutics2013，，： | 1 |
| 7 | Nanosuspensions: a promis- ing drug delivery strategy显示文摘 | Patravale VB Date AA Kulkarni RM | 2004 | J Pharm Pharmacol2004，56，： | 1 |
| 8 | Nanosuspensions:a promising drug delivery strategy显示文摘 | Patravale V B Date A A Kulkarni R M | 2004 | J Pharm Pharmacol2004，56，7： | 1 |
| 9 | Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib 显示文摘 | JOSHI M PATRAVALE V | 2006 | Drug Dev Ind Pharm2006，32，8： | 1 |
| 10 | Nanostructured lipid carrier (NLC) based gel of celecoxib显示文摘 | JOSHI M PATRAVALE V | 2008 | Int J Pharm2008，346，12： | 1 |
| 11 | Carbohyd Polym 显示文摘 | Patale R L Patravale V B O | 2011 | 1 5441: 1-62011，，： | 1 |
| 12 | Mieroemulsion based vaginal gel ot fluconazole:formulation, in vitro and in vivo evaluation 显示文摘 | Baehhav YG Patravale VB | 2009 | Int J Pharm2009，365，12： | 1 |
| 13 | Formulation and evaluation of nanostructured lipid carrier ( NLC )-based gel of valdecoxib 显示文摘 | Joshi M Patravale V | 2006 | Drug Dev Ind Pharm2006，32，8： | 1 |
| 14 | Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria显示文摘 | Vivek Borhade Sulabha Pathak Shobhona Sharma Vandana Patravale | 2014 | Nanomedicine2014，，5： | 1 |
| 15 | Microemulsion based vaginal gel of flu-conazole :formulation,in vitro and in vivo evaluation 显示文摘 | achhav YG Patravale VB | 2009 | Int JPharmf 20092009，，： | 1 |
| 16 | HPLC Determination of Nimesulide from Pharmaceutical Dosage Forms 显示文摘 | Patravale V B D' Souza S Narkar Y | 2001 | J Pharmaceut Biomed2001，25，34： | 1 |
| 17 | Psoriasis clinical implicationsand treatment: a review显示文摘 | Raut AS Prabhu RH Patravale VB | 2013 | Crit Rev Ther Drug Carrier Syst2013，30，3： | 1 |
| 18 | Nanosuspensiorr a promising drug delivery strategy显示文摘 | Patravale VB Date AA Kulkarni RM | 2004 | J Pharm Pharmacol2004，56，7： | 1 |
| 19 | Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles 显示文摘 | Date AA Joshi MD Patravale VB | 2007 | Adv Drug Deliv Rev2007，59，6： | 1 |
| 20 | Nanocar tiers for Effective Topical Delivery of Anti lnfectives显示文摘 | Priyanka Prabhu Vandana Patravale Medha Joshi | 2012 | Current Nanoscience2012，8，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员